Key points are not available for this paper at this time.
The Southwest Oncology Group tested three combinations of drugs with Adriamycin to identify a best regimen for treatment of advanced breast cancer. Adriamycin, cyclophosphamide, and 5-fluorouracil (5FU)(FAC); Adriamycin and cyclosphosphamide (AC); and Adriamycin followed by cyclophosphamide, vincristine, methotrexate, 5FU, and prednisone (A + COMFP) were used in a prospective randomized study of 497 patients with previously untreated metastatic breast cancer. The complete response (CR) plus partial response (PR) was (57/140) 44% with AC, (77/160) 48% with FAC, and (78/148) 46% with A + COMFP. The median length of response was 29, 52, and 37 weeks respectively, with AC, FAC and A + COMFP. The median survival of all patients was 79 weeks; 89 weeks AC, 84 weeks FAC, and 76 weeks with A + COMFP. Toxicity was similar in all three regimens except that leukopenia was more common with FAC.
Tranum et al. (Mon,) studied this question.